Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Primary resistance to integrase strand-transfer inhibitors in Europe

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Casadellà, M, van Ham, PM, Noguera-Julian, M, van Kessel, A, Pou, C, Hofstra, LM, Santos, JR, Garcia, F, Struck, D, Alexiev, I, Bakken Kran, AM, Hoepelman, AI, Kostrikis, LG, Somogyi, S, Liitsola, K, Linka, M, Nielsen, C, Otelea, D, Paraskevis, D, Poljak, M, Puchhammer-Stöckl, E, Staneková, D, Stanojevic, M, Van Laethem, K, Zidovec Lepej, S, Clotet, B, Boucher, CAB, Paredes, R, Wensing, AMJ & SPREAD programme 2015, 'Primary resistance to integrase strand-transfer inhibitors in Europe' The Journal of antimicrobial chemotherapy, bind 70, nr. 10, s. 2885-8. https://doi.org/10.1093/jac/dkv202

APA

Casadellà, M., van Ham, P. M., Noguera-Julian, M., van Kessel, A., Pou, C., Hofstra, L. M., ... SPREAD programme (2015). Primary resistance to integrase strand-transfer inhibitors in Europe. The Journal of antimicrobial chemotherapy, 70(10), 2885-8. https://doi.org/10.1093/jac/dkv202

CBE

Casadellà M, van Ham PM, Noguera-Julian M, van Kessel A, Pou C, Hofstra LM, Santos JR, Garcia F, Struck D, Alexiev I, Bakken Kran AM, Hoepelman AI, Kostrikis LG, Somogyi S, Liitsola K, Linka M, Nielsen C, Otelea D, Paraskevis D, Poljak M, Puchhammer-Stöckl E, Staneková D, Stanojevic M, Van Laethem K, Zidovec Lepej S, Clotet B, Boucher CAB, Paredes R, Wensing AMJ, SPREAD programme. 2015. Primary resistance to integrase strand-transfer inhibitors in Europe. The Journal of antimicrobial chemotherapy. 70(10):2885-8. https://doi.org/10.1093/jac/dkv202

MLA

Vancouver

Casadellà M, van Ham PM, Noguera-Julian M, van Kessel A, Pou C, Hofstra LM o.a. Primary resistance to integrase strand-transfer inhibitors in Europe. The Journal of antimicrobial chemotherapy. 2015 okt;70(10):2885-8. https://doi.org/10.1093/jac/dkv202

Author

Casadellà, M ; van Ham, P M ; Noguera-Julian, M ; van Kessel, A ; Pou, C ; Hofstra, L M ; Santos, J R ; Garcia, F ; Struck, D ; Alexiev, I ; Bakken Kran, A M ; Hoepelman, A I ; Kostrikis, L G ; Somogyi, S ; Liitsola, K ; Linka, M ; Nielsen, C ; Otelea, D ; Paraskevis, D ; Poljak, M ; Puchhammer-Stöckl, E ; Staneková, D ; Stanojevic, M ; Van Laethem, K ; Zidovec Lepej, S ; Clotet, B ; Boucher, C A B ; Paredes, R ; Wensing, A M J ; SPREAD programme. / Primary resistance to integrase strand-transfer inhibitors in Europe. I: The Journal of antimicrobial chemotherapy. 2015 ; Bind 70, Nr. 10. s. 2885-8.

Bibtex

@article{16eb0c1d1b7c4c5fb10ff176eac58661,
title = "Primary resistance to integrase strand-transfer inhibitors in Europe",
abstract = "OBJECTIVES: The objective of this study was to define the natural genotypic variation of the HIV-1 integrase gene across Europe for epidemiological surveillance of integrase strand-transfer inhibitor (InSTI) resistance.METHODS: This was a multicentre, cross-sectional study within the European SPREAD HIV resistance surveillance programme. A representative set of 300 samples was selected from 1950 naive HIV-positive subjects newly diagnosed in 2006-07. The prevalence of InSTI resistance was evaluated using quality-controlled baseline population sequencing of integrase. Signature raltegravir, elvitegravir and dolutegravir resistance mutations were defined according to the IAS-USA 2014 list. In addition, all integrase substitutions relative to HXB2 were identified, including those with a Stanford HIVdb score ≥ 10 to at least one InSTI. To rule out circulation of minority InSTI-resistant HIV, 65 samples were selected for 454 integrase sequencing.RESULTS: For the population sequencing analysis, 278 samples were retrieved and successfully analysed. No signature resistance mutations to any of the InSTIs were detected. Eleven (4{\%}) subjects had mutations at resistance-associated positions with an HIVdb score ≥ 10. Of the 56 samples successfully analysed with 454 sequencing, no InSTI signature mutations were detected, whereas integrase substitutions with an HIVdb score ≥ 10 were found in 8 (14.3{\%}) individuals.CONCLUSIONS: No signature InSTI-resistant variants were circulating in Europe before the introduction of InSTIs. However, polymorphisms contributing to InSTI resistance were not rare. As InSTI use becomes more widespread, continuous surveillance of primary InSTI resistance is warranted. These data will be key to modelling the kinetics of InSTI resistance transmission in Europe in the coming years.",
author = "M Casadell{\`a} and {van Ham}, {P M} and M Noguera-Julian and {van Kessel}, A and C Pou and Hofstra, {L M} and Santos, {J R} and F Garcia and D Struck and I Alexiev and {Bakken Kran}, {A M} and Hoepelman, {A I} and Kostrikis, {L G} and S Somogyi and K Liitsola and M Linka and C Nielsen and D Otelea and D Paraskevis and M Poljak and E Puchhammer-St{\"o}ckl and D Stanekov{\'a} and M Stanojevic and {Van Laethem}, K and {Zidovec Lepej}, S and B Clotet and Boucher, {C A B} and R Paredes and Wensing, {A M J} and {SPREAD programme} and Mathiesen, {Lars Reinhardt}",
note = "{\circledC} The Author 2015. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.",
year = "2015",
month = "10",
doi = "10.1093/jac/dkv202",
language = "English",
volume = "70",
pages = "2885--8",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "10",

}

RIS

TY - JOUR

T1 - Primary resistance to integrase strand-transfer inhibitors in Europe

AU - Casadellà, M

AU - van Ham, P M

AU - Noguera-Julian, M

AU - van Kessel, A

AU - Pou, C

AU - Hofstra, L M

AU - Santos, J R

AU - Garcia, F

AU - Struck, D

AU - Alexiev, I

AU - Bakken Kran, A M

AU - Hoepelman, A I

AU - Kostrikis, L G

AU - Somogyi, S

AU - Liitsola, K

AU - Linka, M

AU - Nielsen, C

AU - Otelea, D

AU - Paraskevis, D

AU - Poljak, M

AU - Puchhammer-Stöckl, E

AU - Staneková, D

AU - Stanojevic, M

AU - Van Laethem, K

AU - Zidovec Lepej, S

AU - Clotet, B

AU - Boucher, C A B

AU - Paredes, R

AU - Wensing, A M J

AU - SPREAD programme

A2 - Mathiesen, Lars Reinhardt

N1 - © The Author 2015. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

PY - 2015/10

Y1 - 2015/10

N2 - OBJECTIVES: The objective of this study was to define the natural genotypic variation of the HIV-1 integrase gene across Europe for epidemiological surveillance of integrase strand-transfer inhibitor (InSTI) resistance.METHODS: This was a multicentre, cross-sectional study within the European SPREAD HIV resistance surveillance programme. A representative set of 300 samples was selected from 1950 naive HIV-positive subjects newly diagnosed in 2006-07. The prevalence of InSTI resistance was evaluated using quality-controlled baseline population sequencing of integrase. Signature raltegravir, elvitegravir and dolutegravir resistance mutations were defined according to the IAS-USA 2014 list. In addition, all integrase substitutions relative to HXB2 were identified, including those with a Stanford HIVdb score ≥ 10 to at least one InSTI. To rule out circulation of minority InSTI-resistant HIV, 65 samples were selected for 454 integrase sequencing.RESULTS: For the population sequencing analysis, 278 samples were retrieved and successfully analysed. No signature resistance mutations to any of the InSTIs were detected. Eleven (4%) subjects had mutations at resistance-associated positions with an HIVdb score ≥ 10. Of the 56 samples successfully analysed with 454 sequencing, no InSTI signature mutations were detected, whereas integrase substitutions with an HIVdb score ≥ 10 were found in 8 (14.3%) individuals.CONCLUSIONS: No signature InSTI-resistant variants were circulating in Europe before the introduction of InSTIs. However, polymorphisms contributing to InSTI resistance were not rare. As InSTI use becomes more widespread, continuous surveillance of primary InSTI resistance is warranted. These data will be key to modelling the kinetics of InSTI resistance transmission in Europe in the coming years.

AB - OBJECTIVES: The objective of this study was to define the natural genotypic variation of the HIV-1 integrase gene across Europe for epidemiological surveillance of integrase strand-transfer inhibitor (InSTI) resistance.METHODS: This was a multicentre, cross-sectional study within the European SPREAD HIV resistance surveillance programme. A representative set of 300 samples was selected from 1950 naive HIV-positive subjects newly diagnosed in 2006-07. The prevalence of InSTI resistance was evaluated using quality-controlled baseline population sequencing of integrase. Signature raltegravir, elvitegravir and dolutegravir resistance mutations were defined according to the IAS-USA 2014 list. In addition, all integrase substitutions relative to HXB2 were identified, including those with a Stanford HIVdb score ≥ 10 to at least one InSTI. To rule out circulation of minority InSTI-resistant HIV, 65 samples were selected for 454 integrase sequencing.RESULTS: For the population sequencing analysis, 278 samples were retrieved and successfully analysed. No signature resistance mutations to any of the InSTIs were detected. Eleven (4%) subjects had mutations at resistance-associated positions with an HIVdb score ≥ 10. Of the 56 samples successfully analysed with 454 sequencing, no InSTI signature mutations were detected, whereas integrase substitutions with an HIVdb score ≥ 10 were found in 8 (14.3%) individuals.CONCLUSIONS: No signature InSTI-resistant variants were circulating in Europe before the introduction of InSTIs. However, polymorphisms contributing to InSTI resistance were not rare. As InSTI use becomes more widespread, continuous surveillance of primary InSTI resistance is warranted. These data will be key to modelling the kinetics of InSTI resistance transmission in Europe in the coming years.

U2 - 10.1093/jac/dkv202

DO - 10.1093/jac/dkv202

M3 - Journal article

VL - 70

SP - 2885

EP - 2888

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - 10

ER -

ID: 46359101